NCT02107885View on ClinicalTrials.gov

Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
SafetyTolerabilityPharmacokinetics
Interventions
DRUG

DS-1971

6 subjects in each group will receive DS-1971.

DRUG

placebo

2 subjects in each group will receive placebo.

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research Ltd., London

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY